As of November 10, 2026, Climb Bio, Inc. is a publicly traded company (Nasdaq: CLYM). The largest holder reporting an active stake on Schedule 13D is RA Capital, at 33%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (15%), Deerfield Mgmt, L.P. (5.25%), BlackRock (5%) (Schedule 13D/A, November 9, 2026).
Is this your company?
About to sign with, pay or invest in Climb Bio, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Climb Bio, Inc. a real, registered company?
- Climb Bio, Inc. files with the SEC under CIK 1768446 (its SEC filings).
- Its shares are listed under the ticker CLYM on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Wellesley Hills, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Climb Bio, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RA Capital (filed 2026-11-09).
Who are Climb Bio, Inc.'s owners and officers?
Climb Bio, Inc.: incorporated in Delaware; business address in Wellesley Hills, Massachusetts; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-11-09).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-05-04)
- : Executive Officer (Form D, 2026-05-04)
- : Executive Officer (Form D, 2026-05-04)
- : Director (Form D, 2026-05-04)
- : Director (Form D, 2026-05-04)
- : Director (Form D, 2026-05-04)
- : Director (Form D, 2026-05-04)
- : Director (Form D, 2026-05-04)
- : Director (Form D, 2026-05-04)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-11-09 | Ra Capital Management, L.P. | 33% |
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 15% |
| Schedule 13G, 2026-10-28 | Deerfield Mgmt, L.P. | 5.25% |
| Schedule 13G, 2026-10-27 | Blackrock, Inc. | 5% |
| Schedule 13G/A, 2026-08-14 | Mpm Bioimpact LLC | 0% |
| Schedule 13G, 2026-07-08 | Fmr LLC | 11.9% |
| Schedule 13D/A, 2026-07-07 | Ra Capital Management, L.P. | 33% |
| Schedule 13D/A, 2026-04-29 | Ra Capital Management, L.P. | 33% |
| Schedule 13G, 2026-02-17 | Mpm Bioimpact LLC | 5.6% |
| Schedule 13D/A, 2025-12-15 | Ra Capital Management, L.P. | 33% |
| Schedule 13D/A, 2025-10-16 | Ai Eti LLC | 0% |
| Schedule 13D/A, 2025-10-07 | Ai Eti LLC | 5.66% |
Questions about who owns Climb Bio, Inc.
Who owns Climb Bio, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Climb Bio, Inc.: Ra Capital Management, L.P. (33%, Schedule 13D/A, filed 2026-11-09), Fmr LLC (15%, Schedule 13G/A, filed 2026-11-05), Deerfield Mgmt, L.P. (5.25%, Schedule 13G, filed 2026-10-28) and Blackrock, Inc. (5%, Schedule 13G, filed 2026-10-27).
Who are the largest shareholders of Climb Bio, Inc.?
By the share each holder's latest filing reports, the largest holders of Climb Bio, Inc. on this page are Ra Capital Management, L.P. (33%), Fmr LLC (15%) and Deerfield Mgmt, L.P. (5.25%).
When did Ra Capital Management, L.P. buy into Climb Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13D/A, filed 2025-12-15, reporting 33%; its latest, Schedule 13D/A filed 2026-11-09, reports 33%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Climb Bio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Climb Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Climb Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Climb Bio, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 467,969 shares (0.80% of shares outstanding) (Form 4, 2026-09-17).
- , the chief executive and president: 87,731 shares (0.15% of shares outstanding) (Form 4, 2026-06-30).
- , a director and 10% owner: 70,000 shares (0.12% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-09-30).
- RA Capital Nexus Fund III, L.P., a director: 70,000 shares (0.12% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-09-30).
- RA Capital, a director and 10% owner: 70,000 shares (0.12% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-09-30).
Shares outstanding: 58,738,178 as of 2026-10-30, from the company's latest SEC cover page.
How much has Climb Bio, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-05-04 | $110.08M | $110.08M |
| Form D, 2024-07-02 | $120M | $120M |
| Form D, 2024-07-02 | $41.87M | $41.87M |
Keep reading
More on Climb Bio, Inc. and the records around it.
Climb Bio, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Company profile and every filing May 2026
- Form D filing May 2026
Companies that share a holder
- Pontifax VI G.P. L.P. also filed stake reports on 3 other companies: Agomab Therapeutics NV (Apr 2026), Keros Therapeutics, Inc. (Oct 2025), LB Pharmaceuticals Inc (Sep 2025)
- MPM BioImpact LLC also filed stake reports on 4 other companies: Context Therapeutics Inc. (Aug 2026), DBV TECHNOLOGIES S.A. (Aug 2026), Forte Biosciences, Inc. (May 2026)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026), BiomX Inc. (Jun 2026)
Related pages
Funding and filing history5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/climb-bio-inc